Table 3 Upcoming cardiovascular outcomes trials in type 2 diabetes
From: Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Study | Drug | Comparator | Primary endpoint | Results |
|---|---|---|---|---|
CANVAS | Canagliflozin | Placebo | Major adverse cardiovascular events, including CV death, non-fatal MI, and non-fatal stroke | 2017 |
CARMELINA | Linagliptin | Placebo | Composite endpoint: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for unstable angina pectoris | 2018 |
EXSCEL | Exenatide once weekly | Placebo | Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke | 2018 |
REWIND | Dulaglutide | Placebo | Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke | 2018 |
DECLARE-TIMI 58 | Dapagliflozin | Placebo | Composite endpoint: CV death, MI or ischemic stroke | 2019 |
CAROLINA | Linagliptin | Glimepiride | Composite endpoint: CV death, non-fatal MI (excluding silent MI), non-fatal stroke and hospitalisation for unstable angina pectoris | 2019 |